What is known and objective: Although non-steroidal antiinflammatory drugs (NSAIDs) have been studied in randomized, controlled trials and meta-analyses in an effort to determine their cardiovascular (CV) risks, no consensus has been reached. These studies continue to raise questions, including whether cyclooxygenase-2 (COX-2) selectivity plays a role in conferring CV risk. We performed a meta-analysis of current literature to determine whether COX-2 selectivity leads to an increased CV risk. Methods: We utilized randomized, controlled trials and prospective cohort studies. We selected eight NSAIDs based on popularity and COX selectivity and conducted a search of the MEDLINE, EMBASE, and Cochrane databases. Primary endpoints included any myocardial infarction (MI), any stroke, CV death, and a combination of all three (composite CV outcomes). Twenty-six studies were found that met inclusion and exclusion criteria. Comparisons were made between all included drugs, against placebo, and against non-selective NSAIDs (nsNSAIDs). Drugs were also compared against COX-2 selective inhibitors (COXIBs) with and without inclusion of rofecoxib.
literature discussion. [10] [11] [12] [13] The COXIBs were developed to ameliorate the GI side effects of the nsNSAIDs. 14 After the APPROVe trial showed increased incidence of myocardial infarction with rofecoxib, 15 rofecoxib was removed from the market and concern of the cardiovascular (CV) risks of NSAIDs, particularly the COXIBs, has risen. 16, 17 The objective of this meta-analysis was to add to the growing literature on the CV risk of NSAIDs. With the exception of rofecoxib, controversy continues on the existence and extent of NSAID-induced CV adverse effects. COX-2 selectivity has been discussed as posing an increased risk; 18 however, this has remained controversial as data on individual COXIBs have been heterogeneous. 2, 4 For stroke outcomes in particular, debate continues with the individual NSAIDs as to the increased risk. 4, 19 Meta-analyses and systematic reviews also do not reach a consensus on MI, stroke and CV death risks with NSAIDs.
Due to this continued controversy, we performed a metaanalysis examining eight NSAIDs (three nsNSAIDs and five COXIBs) both as individual drugs and by group (nsNSAID vs. COXIBs) to determine whether risk is related to COX-2 selectivity. Data were assessed both with and without rofecoxib to determine the level of bias that rofecoxib may present. The analysis included randomized controlled trials and prospective cohorts that compared NSAIDs either head-to-head or vs. placebo.
METHODS

Inclusion and exclusion criteria
We considered randomized controlled trials and prospective cohort studies with comparisons between NSAIDs or against placebo. Eight NSAIDs were included in this study: ibuprofen, diclofenac, naproxen, meloxicam, etoricoxib, celecoxib, lumiracoxib and rofecoxib. The three former were chosen due to their non-selectivity (and, in the case of naproxen and ibuprofen, their use as common over-the-counter agents), and the latter five were chosen due to their degree of COX-2 selectivity. Rofecoxib was also included due to its known CV adverse effects. To meet inclusion criteria, trials had to contain reported CV events, defined as MI, stroke or death from a CV event, for one of the included NSAIDs. Exclusion criteria included non-English language studies, nonhuman studies, duration of treatment less than 1 month, and studies lacking reported CV data. Studies with treatment periods of less than 1 month were excluded because they did not assess chronic use.
Data retrieval
We searched all relevant studies from three databases: MEDLINE (through PubMed), Cochrane Central Register of Controlled Trials and EMBASE. Key terms used to search MEDLINE, EMBASE, and Potentially relevant studies identified and screened for retrieval through EMBASE, MEDLINE and Cochrane between May 2014 and August 2014 (n = 4985) Randomized, controlled trials and prospective cohorts retrieved for more detailed evaluation (n = 553)
Studies included in the final analysis (n = 26)
Studies excluded for not matching study criteria or having insufficient CV data (n = 527)
Studies excluded for nonEnglish, and non-human. Also studies other than randomized, controlled trials and cohorts (n = 4432) Fig. 1 . Flow of included studies. Numbers of studies (n) that were filtered at each step are shown. Cochrane databases included the name of the NSAID and CV outcome (MI, stroke and CV). Retrieved studies were filtered and manually searched by authors for adherence to inclusion and exclusion criteria (Fig. 1 ). Included study characteristics are shown in Table 1 .
Outcomes
Primary endpoints included were any MI, any stroke, and CV death. A composite CV outcome (composite CV) was also established for each NSAID and was defined as the total number of events combined of any MI, any stroke and CV death.
Data treatment and statistical analysis
All statistical analyses on extracted data were performed using the Comprehensive Meta-Analysis version 2.0 software program (Biostat, Inc., Englewood, NJ, USA). Odds ratios (ORs) were used with 95% confidence intervals (CI). Statistical significance was set at P < 0Á05. Precision funnel plots were developed to determine heterogeneity. Heterogeneity was further assessed using Egger's test (figures and data are not shown).
Comparisons
Five comparisons were drawn in this study. For each NSAID, the NSAID of interest was compared with placebo, all NSAIDs, nsNSAIDs (ibuprofen, diclofenac and naproxen), COXIBs (rofecoxib, celecoxib, etoricoxib and lumiracoxib) and COXIBs without inclusion of rofecoxib. These comparisons were made for each outcome (MI, stroke, CV death and composite CV). Three studies, CADEUS, Reicin 2002 and PROBE, defined a group of NSAIDs as nsNSAIDs. These groups were treated in our analysis similar to ibuprofen, diclofenac and naproxen; the composition of each group is listed in Table 2 . Individual NSAIDs other than the eight NSAIDs of interest were not included in our comparisons. In studies that compared different regimens of the same NSAID, the data from the two regimens were combined for analysis.
RESULTS
The flow chart of included and excluded studies is shown in Fig. 1 . Study retrieval occurred between May 2014 and August 2014 and was performed by two authors. The initial search retrieved 4985 articles, of which 26 studies involving 24 randomized controlled trials and two prospective cohort studies were included in the analysis (Table 1 ). In total, 4432 studies were excluded due to either not meeting inclusion criteria, meeting exclusion criteria or were not relevant. Celecoxib was the most studied NSAID (12 studies) and was compared with all NSAIDs in this study along with placebo. Ibuprofen was studied the least (two studies), but was compared to three NSAIDs (celecoxib, lumiracoxib and naproxen; Tables 2 and  3) . Table 3 shows the number of comparisons an individual NSAID had to other NSAIDs in the included studies. Numbers in parentheses show how many different NSAIDs were compared to the NSAID of interest. The study involving meloxicam did not meet inclusion criteria; therefore, meloxicam was not included in statistical analysis. Of all 26 studies, 228 391 patients were represented, with celecoxib representing the most at 28Á6% (n = 65 341) and ibuprofen the least at 2Á79% (n = 6382). Forest plots containing the odds ratios and confidence intervals of cumulative events are shown in Figs 2-6. A graph showing COX-2 selectivity of studied NSAIDs is shown in Fig. 7 . Forest plots containing odds ratios of individual studies and numerical cumulative odds ratios and confidence intervals are provided in the Appendix S1. Heterogeneity was assessed for each medication and outcome. Two analyses showed heterogeneity: ibuprofen in the CV death outcome and rofecoxib in the stroke outcome.
Myocardial infarction
Rofecoxib was the only NSAID that showed an increase in MI (Figs 2-5 ). This held true when compared to all NSAIDs (OR: 1Á811, 95% CI: 1Á379-2Á378, P < 0Á001), placebo (OR: 1Á655: 95% CI: 1Á029-2Á661, P = 0Á038), nsNSAIDs (OR: 2Á155, 95% CI: 1Á146-4Á053, P = 0Á017) and COXIBs (OR: 1Á800, 95% CI: 1Á217-2Á662, P = 0Á003). Celecoxib and naproxen both showed a decrease in MI when compared to other COXIBs (OR: 0Á583, 95% CI: 0Á396-0Á857, P = 0Á006) and (OR: 0Á609, 95% CI: 0Á375-0Á989, P = 0Á045), respectively] (Fig. 5) ; however, this difference did not exist when rofecoxib was removed from the comparison (Fig. 6 ). All other NSAIDs did not show any statistical difference. 
Stroke
Celecoxib exhibited a decrease in stroke when compared with all NSAIDs (OR: 0Á603, 95% CI: 0Á410-0Á887, P = 0Á010), nsNSAIDs (OR: 0Á517, 95% CI: 0Á287-0Á929, P = 0Á027), and COXIBs (OR: 0Á509, 95% CI: 0Á280-0Á925, P = 0Á027) (Figs 2, 4, 5). No difference was found when compared to placebo (Fig. 3) or when rofecoxib was removed from the COXIBs (Fig. 6 ). Rofecoxib exhibited a higher incidence in stroke when compared with all NSAIDs (OR: 1Á488, 95% CI: 1Á027-2Á155, P = 0Á036) and other COXIBs (OR: 1Á933, 95% CI: 1Á052-3Á549, P = 0Á034) (Figs. 2, 5 ).
CV death
No NSAID exhibited significant difference in CV death in any outcome (Figs. 2-6 ).
Composite CV
Celecoxib exhibited an overall lower incidence of the composite CV outcome when compared with all NSAIDs (OR: 0Á805, 95%
CI: 0Á658-0Á986, P = 0Á036) and the other COXIBs (OR: 0Á557, 95% CI: 0Á404-0Á767, P < 0Á001) (Figs. 2, 5 ). This benefit did not occur when rofecoxib was excluded from the COXIBs (Fig. 6) . Rofecoxib demonstrated an increase in overall events when compared against all NSAIDs (OR: 1Á612, 95% CI: 1Á313-1Á981, P < 0Á001), placebo (OR: 1Á572, 95% CI: 1Á123-2Á201, P = 0Á008) and other COXIBs (OR: 1Á838, 95% CI: 1Á323-2Á554, P < 0Á001) (Figs. 2, 3, 5 ).
DISCUSSION
It is thought, in theory, that the selectivity of the NSAIDs for the COX-2 enzyme governs the CV toxicity profile, possibly due to an imbalance in COX-1 and COX-2 activities. 1, 16, 20 This distinction has become ambiguous at best as results of several studies have shown that CV risk also exists for the nsNSAIDs. 16 A lack of a clear correlation between risk and COX-2 selectivity has also been established. 2 Abraham et al. 18 found an increase in cardiovascular adverse events of highly selective NSAIDs over moderately and poorly selective NSAIDs; however, the moderately selective NSAIDs, including celecoxib, did not exhibit a statistically significant difference from the poorly selective NSAIDs. In addition to this, rofecoxib carried the highest risk, even above other highly selective NSAIDs. COX-2 selectivity of NSAIDs has been established for all NSAIDs, and the selectivity of the seven NSAIDs in this study is shown graphically in Fig. 7 . Another problem with the selectivity hypothesis is the case of lumiracoxib, the most selective NSAID for COX-2 included in the article. 6 A meta-analysis of randomized, controlled trials looking at the CV safety of lumiracoxib found no difference in CV outcomes between NSAIDs or placebo; however, the data in the study did suffer from wide confidence intervals so, as suggested by the authors, further research is needed. 21 Furthermore, etoricoxib, the third most selective COXIB examined in our study, has not shown a consistently increased CV risk. When compared to diclofenac in the MEDAL trial, etoricoxib demonstrated no significant difference in MI, thrombotic CV, CV, or cerebrovascular events. 22 Furthermore, in a study comparing etoricoxib to placebo for 6 weeks and to naproxen for 52 weeks, etoricoxib was found to have no difference in CV events. 23 This variation in the risk of COXIBs and the findings of risk within the nsNSAIDs should lead to considerations of other mechanisms at work in the role of CV risk.
It has been proposed that the CV toxic effects are a result of differences in physiochemical properties between different NSAIDs. 17, 24, 25 Other investigators have attributed the effects of some toxic NSAIDs to an increase in susceptibility of cardiomyocyte membranes to oxidative damage or an increase in a toxic metabolite of arachidonic acid. 26, 27 As more research is compiled with NSAIDs, these physiochemical properties will become more elucidated, and a potential answer can be found for the cause of CV risk.
Celecoxib was found to confer a lower risk in this meta-analysis when compared to nsNSAIDs, COXIBs and all NSAIDs; however, there was no difference when rofecoxib was removed from the COXIBs comparison. Of note, celecoxib was only compared to etoricoxib in two studies and to rofecoxib in two studies (Table 3) . The rofecoxib studies accounted for 98Á8% of the patients. The incidence of lower risk of celecoxib over rofecoxib is supported in the literature with several studies finding a statistical difference with rofecoxib but not celecoxib when compared to placebo. 28, 29 The statistically significant difference of celecoxib against the nsNSAIDs and all NSAIDs also warrants further discussion. Celecoxib was compared to all four nsNSAIDs in five studies along with inclusion of nsNSAIDs from the CADEUS and PROBE trials. Celecoxib also showed statistically significant fewer stroke events when compared to diclofenac and ibuprofen in the CLASS study. 30, 31 This finding also confirms the findings of Park et al. 19 that the evidence for stroke risk of celecoxib is too divergent to draw conclusions from the current literature. Celecoxib has been found in many studies to pose a nonsignificant difference in risk when compared to other NSAIDs, 14, 18, 32, 33 and as in this meta-analysis and the CLASS trial, it was found to have lower rates than nsNSAIDs.
In this study, celecoxib also demonstrated a lower event rate with the composite CV outcome. This is not a surprising observation as fewer events were demonstrated against two of the three groups (nsNSAIDs and COXIBs). When compared to placebo, the odds ratio of celecoxib was 1Á520; however, this did not reach statistical significance with addition of confidence intervals. 
Myocardial infarction outcomes
An increase in MIs observed with rofecoxib was the beginning of the research into the CV side effects of NSAIDs. [14] [15] [16] 33 This association was supported by our findings and is not disputed within the literature. Rofecoxib has continued to be included in meta-analyses as a comparator due to its known adverse effects; however, its known risk has potential to skew results when grouped with other COXIBs. This effect was seen in our findings when naproxen and celecoxib were compared to the COXIBs. When rofecoxib was removed from the comparison, neither NSAID showed a statistical difference.
A difference may exist in the type of MI caused by NSAIDs. In one systematic review of six randomized trials and observational studies, NSAID use was found to cause an increase in non-fatal MI but not in fatal MI. 34 The authors hypothesized this was possibly due to the antithrombotic effects of partial COX-1 inhibition counteracting the prothrombotic effects of COX-2 inhibition. Another study found that NSAID use led to an increase in non-ST-segment elevation acute coronary syndromes but not ST-segment elevations. 34, 35 These findings and theories only demonstrate that further research is needed to fully elucidate the cause for this imbalance in MI occurrence.
Stroke outcomes
Stroke risk with NSAIDs continues to be a great source of debate within the literature. Aside from rofecoxib, there is no consensus on which NSAIDs carry the highest risk or any risk at all. 4 Heterogeneity of the data continues to exist when COX selectivity is considered. One source for this lack of clarity may arise from the scarcity of events within studies. In our study, only 263 stroke events occurred of the 228 391 patients or 0Á1% of the patients. Rofecoxib significantly increased stroke when compared to the COXIBs; however, celecoxib was the only NSAID that rofecoxib was compared to in this group.
CV death outcomes
No NSAID studied reached statistical significance in regard to CV death. For many of the NSAIDs, little data was provided for CV death. In addition, confidence intervals were often wide. This lack of data hinders a determination of a true risk. Other studies have found varying degrees of risk for individual NSAIDs; however, there is little consensus between studies as to which drugs pose a risk and to what extent. 4 Adding to the controversy is the relatively small number of events and failure to account for the risk associated with chronic inflammatory states. 4 Our study did not lend further insight into this outcome due to the lack of reported events.
Composite CV outcomes
A statistically lower rate of stroke and MI was observed with celecoxib; therefore, a lower composite CV risk should not be surprising. For the composite CV risk of celecoxib vs. other COXIBs (without rofecoxib), the confidence interval was wide, and the analysis was composed of only four studies with etoricoxib serving as the comparator in three of the four studies.
Strengths and weaknesses
This meta-analysis set out to compare eight NSAIDs; however, the study involving meloxicam did not meet inclusion criteria; therefore, it was not included in the analysis. Meloxicam is an older NSAID with a stronger selectivity for COX-2. A comparison with meloxicam would have been beneficial to further distinguish the role of selectivity in CV risk.
Additionally, several of the comparisons suffered from a lack of data and studies, particularly for individual NSAIDs compared to placebo, and for the CV death outcome. This lack of direct comparisons resulted in wide confidence intervals, which could lead to potential error. Often times, NSAIDs were only compared to one or two other NSAIDs when the data were viewed as groups (nsNSAIDs and COXIBs). This prevented a robust comparison of the NSAID against a group. Comparisons against all NSAIDs corrected for this and offered a more robust comparison.
This meta-analysis did not address drug dose, duration, concurrent aspirin use, or baseline CV risk. Dose effects have been established in some studies; 36, 37 however, event rates usually increased at doses above clinical use. 4 Because of the design of our study, dose differences were not approached due to the large and complicated nature of the data. Duration was also not addressed due to similar issues; however, the role of duration continues to be debated. 4 The influence of aspirin use and baseline CV risk, although not researched in this study, cannot be ruled out. Abraham et al. 18 found an elevated event rate in those with increased baseline risk. Aspirin use is a significant confounding variable in this study and was not addressed due to differences in reporting between studies.
This meta-analysis was strong in that it was comprised of a large patient population spanning multiple disease states and multiple NSAIDs. It included multiple outcomes along with a composite of these outcomes to assess risk from various scenarios. It also compared the class of drug (nsNSAID and COXIBs) vs. each other and vs. placebo to understand how these groups compare in outcomes. Lastly, the data were analysed both with and without rofecoxib to understand the extent of the role it plays in the CV adverse events attributed to the COXIBs.
WHAT IS NEW AND CONCLUSION
The findings of this meta-analysis suggest that CV adverse effects of NSAIDs may not be based on the COX-2 selectivity of NSAIDs. Rofecoxib was the only NSAID to show an increase in CV adverse effects whereas other COXIBs demonstrated no difference The selectivity of the seven NSAIDs included in this study is shown graphically here. Naproxen shows the least selectivity for COX-2 whereas lumiracoxib exhibits the most.
compared to placebo and nsNSAIDs. Celecoxib showed a lower incidence of risk in stroke when compared to the nsNSAIDs further adding to the discussion of the role of celecoxib and the NSAID class in the risk of stroke. Further research is needed to determine the extent of NSAID-induced CV adverse events for both the class and the individual members. Attention should begin to be focused more on the physiochemical, pharmacokinetic, and pharmacodynamic effects of the NSAIDs as a potential explanation for the observed CV effects.
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